Sleep Apnea and Atrial Fibrillation.

Atrial Fibrillation Catheter Ablation Continuous Positive Airway Pressure Humans Sleep Apnea Syndromes
Atrial fibrillation Continuous positive air pressure (CPAP) Polygraphy Pulmonary vein isolation Screening Sleep apnea

Journal

Cardiac electrophysiology clinics
ISSN: 1877-9190
Titre abrégé: Card Electrophysiol Clin
Pays: United States
ID NLM: 101549998

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 31 1 2021
pubmed: 1 2 2021
medline: 29 9 2021
Statut: ppublish

Résumé

Obstructive sleep apnea (OSA) creates a complex and dynamic substrate for atrial fibrillation (AF), which is characterized by structural remodeling as a result of long-term OSA as well as transient and acute apnea-associated transient atrial electrophysiological changes. OSA is present in 21% to 74% of patients with AF, and nonrandomized studies suggest that treatment of OSA by continuous positive airway pressure may help to maintain sinus rhythm after electrical cardioversion and improve catheter ablation success rates. Management of OSA in patients with AF requires a close interdisciplinary collaboration between the electrophysiologist/cardiologist and sleep specialists.

Identifiants

DOI: 10.1016/j.ccep.2020.10.003 PMID: 33516410
pubmed: 33516410
pii: S1877-9182(20)30105-2
doi: 10.1016/j.ccep.2020.10.003
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

87-94

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure Dr D. Linz is supported by a Beacon Research Fellowship by the University of Adelaide. Drs J.M. Kalman and P. Sanders are supported by Practitioner Fellowships from the National Health and Medical Research Council of Australia. Dr P. Sanders is supported by the National Heart Foundation of Australia. Dr D. Linz reports having served on the advisory board of LivaNova, Respicardia, and Medtronic. Dr D. Linz reports having received lecture and/or consulting fees from LivaNova, Biosense-Webster, Medtronic, Pfizer, Bayer, and ResMed. Dr D. Linz reports having received research funding from Sanofi, ResMed, and Medtronic. Dr P. Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, and CathRx. Dr P. Sanders reports having received lecture and/or consulting fees from Biosense-Webster, Medtronic, St Jude Medical, and Boston Scientific. Dr P. Sanders reports having received research funding from Medtronic, St Jude Medical, Boston Scientific, Biotronik, and Sorin. The other authors have nothing to disclose.

Auteurs

Dominik Linz (D)

Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute, Maastricht, the Netherlands; Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: Dominik.Linz@adelaide.edu.au.

Stanley Nattel (S)

Department of Medicine, Montreal Heart Institute and Université de Montréal, Montréal, Quebec, Canada; Department of Pharmacology and Therapeutics, McGill University, 3655 Prom. Sir Willian Osler, Montreal, Quebec H3G 1Y6, Canada; Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.

Jonathan M Kalman (JM)

Department of Cardiology, Royal Melbourne Hospital and Department of Medicine, University of Melbourne, 300 Grattan Street, Melbourne, Victoria, Australia.

Prashanthan Sanders (P)

Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Troubles du rythme cardiaque › Fibrillation auriculaire › Sleep Apnea and Atrial Fibrillation.
questionsmedicales.fr › Procédures de chirurgie opératoire › Techniques d'ablation › Ablation par radiofréquence › Ablation par cathéter › Sleep Apnea and Atrial Fibrillation.
questionsmedicales.fr › Thérapeutique › Thérapie respiratoire › Ventilation artificielle › Ventilation à pression positive › Ventilation en pression positive continue › Sleep Apnea and Atrial Fibrillation.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Sleep Apnea and Atrial Fibrillation.
questionsmedicales.fr › Maladies du système nerveux › Syndromes d'apnées du sommeil › Sleep Apnea and Atrial Fibrillation.